文献速递前列腺癌

在接受雄激素剥夺治疗的前列腺癌男性中预防骨质疏松:系统综述与Meta分析

Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
PubMed 文献 · Eur Urol Oncol · 2018-11-24

该系统综述与Meta分析检索了截至2016年7月20日的Medline、Embase和EBM Reviews数据库,纳入25项研究(其中13项有定量数据)。双膦酸盐可显著改善腰椎、股骨颈和全髋骨密度,SERMs效果较弱,运动方案单独应用不充分,地舒单抗无法定量分析。结论认为双膦酸盐和地舒单抗有效,SERMs是效果较弱的替代选择,运动应作为辅助。

要点

  • 双膦酸盐显著改善腰椎、股骨颈和全髋骨密度。
  • SERMs效果较弱,运动方案单独应用不充分。
  • 地舒单抗无法进行定量分析,但结论认为有效。

核心结论

  • 双膦酸盐和地舒单抗是预防接受ADT的前列腺癌男性骨密度丢失的有效治疗。
  • SERMs是效果较弱的替代选择。
  • 运动方案单独应用不充分,但可作为整体照护的辅助手段。

研究设计与样本

  • 系统综述与Meta分析,检索Medline、Embase和EBM Reviews数据库,检索日期为2016年7月20日。
  • 纳入25项研究,其中13项有足够定量数据进行骨密度丢失的Meta分析。

主要发现

  • 双膦酸盐组腰椎骨密度平均差为7.09%(95%CI 5.05-9.13%;p<0.00001)。
  • 双膦酸盐组股骨颈骨密度平均差为4.63%(95%CI 0.87-8.4;p=0.02)。
  • 双膦酸盐组全髋骨密度平均差为3.16%(95%CI 0.09-6.23%;p=0.04)。
  • SERMs效果较弱,运动研究效果不一致,地舒单抗无法定量分析。

关键数值与推荐

  • 双膦酸盐在腰椎、股骨颈和全髋骨密度均显示显著改善。
  • SERMs为效果较弱的替代选择。
  • 运动方案单独应用不充分,可作为辅助。

临床怎么用

  • 作者认为应使用双膦酸盐、地舒单抗或SERMs,并鼓励运动。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Advanced prostate cancer (PCa) is treated with androgen deprivation therapy (ADT) which results in loss of bone mineral density (BMD) and osteoporosis. OBJECTIVE: To perform a systematic review and meta-analysis of evidence to determine the most effective methods of preventing BMD loss in patients with PCa treated with ADT. EVIDENCE ACQUISITION: A systematic search of the Medline, Embase, and EBM Reviews databases was conducted on July 20, 2016 to identify studies on men who received an intervention to prevent osteoporosis after diagnosis of PCa and treatment with ADT. The Preferred Reporting Items for Systematic Reviews and Meta-analyses statement was followed and the studies found were critically appraised. EVIDENCE SYNTHESIS: Twenty-five studies were included in the review and 13 had quantitative data sufficient for meta-analysis of BMD loss. Bisphosphonates led to a significant improvement in areas assessed: the mean difference was 7.09% (95% confidence interval [CI] 5.05-9.13%; p<0.00001) for lumbar BMD, 4.63% (95% CI 0.87-8.4; p=0.02) for femoral neck BMD, and 3.16% (95% CI 0.09-6.23%; p=0.04) for total hip BMD. Selective estrogen receptor modulators (SERMs) were less effective, exercise studies had inconsistent effects, and denosumab could not be quantitatively analyzed. CONCLUSIONS: Bisphosphonates and denosumab are effective treatments in preventing BMD loss in men with PCa taking ADT. SERMs are a less effective alternative. Exercise programs are insufficient in isolation but have a role as an adjunct for holistic care. PATIENT SUMMARY: In this review we determined the best option for preventing osteoporosis in men with prostate cancer being treated with androgen deprivation therapy. We found that bisphosphonates, denosumab, and selective estrogen receptor modulators (SERMs) were effective, but exercise was not useful in isolation. We conclude that bisphosphonates, denosumab, or SERMs should be used and exercise encouraged.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Joseph JS, Lam V, Patel MI, et al. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Eur Urol Oncol. 2018. PMID: 31411986. doi:10.1016/j.euo.2018.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。